1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Scots fund Novartis' Glivec but not Roche's RoActemra or GSK's Benlysta

 
• By Francesca Bruce

The Scottish Medicines Consortium, Scotland's health technology appraisal body, has agreed to make available on the local NHS Novartis' Glivec (imatinib) for some gastrointestinal stromal tumour (GIST) patients for a longer duration of treatment. However, neither Roche nor GSK were able to convince the consortium to recommend their drugs, RoActemra (tocilizumab, as monotherapy) and Benlysta (belimumab) respectively.

The Scottish Medicines Consortium, Scotland's health technology appraisal body, has agreed to make available on the local NHS Novartis' Glivec (imatinib) for some gastrointestinal stromal tumour (GIST) patients for a longer duration of treatment. However, neither Roche nor GSK were able to convince the consortium to recommend their drugs, RoActemra (tocilizumab, as monotherapy) and Benlysta (belimumab) respectively.

The SMC now says that patients can receive Glivec for the adjuvant treatment of adults at significant risk of relapse...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

UCB Takes A Bow as Bimzelx HS Launch Achieves Lift-Off

 
• By Manas Mishra

The Belgian company has raised its outlook for full-year sales following a strong launch for Bimzelx in hidradenitis suppurativa in the first half of 2025.

Vyne Seeks Partner For Repibresib After Phase IIb Vitiligo Fail

 
• By Alaric DeArment

The Phase IIb study failed its primary and a key secondary endpoint, but showed activity on another key secondary and an exploratory endpoint.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist boosts its sales force ahead of the launch of Anzupgo.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 
• By Anju Ghangurde

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

More from Therapeutic Category

Vedanta’s Live Bacteria Reach A Dead End In Ulcerative Colitis

 
• By Andrew McConaghie

The microbiome-based company’s trial of VE202 in ulcerative colitis has failed in Phase II, but its ongoing Phase III study in C difficile infection is more promising.

Post-GLP-1 Patients Are Significant Opportunity, But Response Sees More

 
• By Alaric DeArment

The company will move ahead in testing RDX-002 among overweight and obese patients coming off GLP-1s, but the CEO said antipsychotic-induced weight gain could represent a multibillion-dollar market.

PureTech’s New Spin-Off Wants Partners For Pulmonary Fibrosis Drug

 
• By Andrew McConaghie

Deupirfenidone hit its Phase II endpoint but the program remains risky and PureTech’s new Celea Therapeutics will aim to pull in extra funding for its late-stage development.